Dernière mise à jour : mars 29, 2021
Détails
FichiersNom générique:
frémanézumab
État du projet:
Terminé
Domaine thérapeutique:
La migraine
Fabricant:
Teva Canada Innovation
Marque de commerce:
Ajovy
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
SR0641-000
Statut de l’AC au moment du dépôt:
Post AC
Biosimilaire:
Non
Manufacturer Requested Reimbursement Criteria1:
Dans la prévention de la migraine chez l'adulte ayant au moins quatre jours de migraine par mois.
Type de demande:
Initiale
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input open | March 30, 2020 |
| Call for patient input closed | May 20, 2020 |
| Clarification: - Patient input submission received from Migraine Canada and Migraine Quebec | |
| Submission received | June 03, 2020 |
| Submission accepted | September 22, 2020 |
| Clarification: - Submission was not accepted for review on 17 June 2020 | |
| Review initiated | September 23, 2020 |
| Draft CADTH review report(s) provided to sponsor for comment | December 18, 2020 |
| Deadline for sponsors comments | January 06, 2021 |
| CADTH responses on draft review report(s) provided to sponsor | February 04, 2021 |
| CADTH review report(s) and responses to comments provided to sponsor | February 04, 2021 |
| Expert committee meeting (initial) | February 17, 2021 |
| Draft recommendation issued to sponsor | March 03, 2021 |
| End of embargo period | March 17, 2021 |
| Final recommendation issued to sponsor and drug plans | March 24, 2021 |
| Final recommendation posted | March 26, 2021 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | April 08, 2021 |
| CADTH review report(s) posted | May 28, 2021 |
Fichiers
Dernière mise à jour : mars 29, 2021